新股预览：讯飞医疗科技

Investment Rating - The report assigns a rating of ★★★☆☆ to the company, indicating a moderate investment outlook [8]. Core Insights - The company is positioned as a leader in the AI-enabled healthcare solutions sector, providing a range of services from health risk alerts to chronic disease management [5]. - The AI healthcare market in mainland China is projected to grow significantly, with an expected increase from RMB 8.8 billion in 2023 to RMB 315.7 billion by 2033, reflecting a compound annual growth rate (CAGR) of 43.1% [6]. - The company has developed the world's first AI robot that has passed the national medical licensing examination, giving it a competitive edge in the market [6]. - The company has built a substantial customer base, serving 1,007 clients by the end of 2023, with expectations to reach 1,207 by mid-2024 [7]. Financial Summary - Revenue figures for the company are as follows: RMB 3.72 billion in 2021, RMB 4.72 billion in 2022, and projected RMB 5.56 billion in 2023 [3]. - Shareholder profit (loss) figures are reported as -RMB 0.84 billion in 2021, -RMB 1.89 billion in 2022, and -RMB 1.45 billion in 2023 [4].